Premium Nahrungsergänzungsmittel | artgerecht

Helicobacter pylori Eradication: Treatment Guide

Helicobacter pylori eradication refers to the targeted antibiotic-based treatment to completely eliminate the stomach bacterium Helicobacter pylori and prevent related diseases.

Regular tips about health Regular tips about health

Things worth knowing about "Helicobacter pylori Eradication"

Helicobacter pylori eradication refers to the targeted antibiotic-based treatment to completely eliminate the stomach bacterium Helicobacter pylori and prevent related diseases.

What Is Helicobacter pylori Eradication?

Helicobacter pylori eradication is a medical treatment aimed at completely eliminating the bacterium Helicobacter pylori from the stomach and gastrointestinal tract. Helicobacter pylori is a gram-negative bacterium that colonizes the gastric mucosa and can cause a range of digestive disorders. Given its widespread global prevalence, eradication therapy is one of the most commonly performed treatments in gastroenterology.

Causes and Indications

Eradication therapy is recommended when a Helicobacter pylori infection has been confirmed and certain conditions are present or a significant risk of complications exists. Common indications include:

Gastric ulcer or duodenal ulcer
Chronic gastritis (type B, H. pylori-associated)
MALT lymphoma of the stomach
History of early-stage gastric cancer treatment
Long-term use of NSAIDs (non-steroidal anti-inflammatory drugs) or aspirin in patients with confirmed H. pylori infection
Functional dyspepsia with confirmed H. pylori infection

Mechanism of Action and Treatment Regimens

Eradication therapy typically combines several agents to attack the bacterium through different pathways and to overcome antibiotic resistance. The cornerstone of every regimen is a proton pump inhibitor (PPI), which reduces gastric acid production and creates a more favorable environment for antibiotic activity.

Classic Triple Therapy (Standard)

The most commonly used first-line regimen is triple therapy, consisting of:

A proton pump inhibitor (e.g., omeprazole, pantoprazole)
Clarithromycin (antibiotic)
Amoxicillin (antibiotic) or alternatively metronidazole

Treatment typically lasts 7 to 14 days. A 14-day course is increasingly preferred as it achieves higher eradication rates.

Bismuth-Based Quadruple Therapy

In cases of clarithromycin resistance or failure of triple therapy, a quadruple therapy is used, consisting of:

Proton pump inhibitor
Bismuth subcitrate or bismuth subsalicylate
Tetracycline
Metronidazole

Sequential and Concomitant Therapy

Alternative options include sequential therapy (successive administration of different antibiotics) and concomitant therapy (simultaneous use of four agents without bismuth), particularly recommended in regions with high local resistance rates.

Diagnosis and Monitoring

Before treatment, infection is confirmed using various diagnostic methods:

Urea breath test (13C-UBT): the non-invasive gold standard for diagnosis and follow-up
Stool antigen test: detects H. pylori antigens in stool samples
Upper endoscopy (gastroscopy) with biopsy for culture, histology, or rapid urease test
Serology: blood test for H. pylori antibodies (less suitable for confirming eradication success)

After completing therapy, treatment success should be confirmed no earlier than 4 weeks after finishing antibiotics, preferably using the urea breath test or stool antigen test.

Side Effects of Therapy

Eradication therapy is generally well tolerated, but side effects may occur:

Nausea, vomiting, and diarrhea
Metallic taste in the mouth (especially with metronidazole)
Disruption of the gut microbiome
Allergic reactions to antibiotics (especially amoxicillin)
In rare cases: Clostridioides difficile-associated diarrhea

Treatment Success and Antibiotic Resistance

When therapy is carried out correctly, eradication rates range between 80 and 95 percent. Rising antibiotic resistance, particularly to clarithromycin and metronidazole, represents a growing challenge. Current guidelines recommend considering local resistance patterns when selecting a treatment regimen. If first-line therapy fails, resistance testing should ideally be performed before initiating second-line treatment.

References

Malfertheiner P. et al. - Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut, 2022. DOI: 10.1136/gutjnl-2022-327745
Chey W.D., Leontiadis G.I., Howden C.W., Moss S.F. - ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology, 2017. DOI: 10.1038/ajg.2016.563
World Health Organization (WHO) - Helicobacter pylori. Fact Sheet, 2023. Available at: www.who.int

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.